Roberta Napolitano
Overview
Explore the profile of Roberta Napolitano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
220
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Napolitano R, Guidolin N, Boccalon M, Fringuello Mingo A, Colombo Serra S, Buonsanti F, et al.
Adv Sci (Weinh)
. 2025 Feb;
:e2415321.
PMID: 39960335
Magnetic Resonance Imaging (MRI) plays a vital role in the accurate diagnosis of numerous human diseases and disorders, with Gd(III)-based contrast agents (GBCAs) being used in ≈30%-40% of procedures, resulting...
2.
Luserna di Rora A, Ghetti M, Ledda L, Ferrari A, Bocconcelli M, Padella A, et al.
Cell Biol Toxicol
. 2024 Aug;
40(1):73.
PMID: 39215871
No abstract available.
3.
Blua F, Boccalon M, Rolando B, Napolitano R, Arena F, Blasi F, et al.
Bioorg Chem
. 2024 May;
148:107462.
PMID: 38776650
Imaging in the shortwave infrared (SWIR, 1000-1700 nm) region is gaining traction for biomedical applications, leading to an in-depth search for fluorophores emitting at these wavelengths. The development of SWIR...
4.
Arena F, La Cava F, Faletto D, Roberto M, Crivellin F, Stummo F, et al.
PNAS Nexus
. 2023 Aug;
2(8):pgad250.
PMID: 37575672
Commercially available near-infrared (NIR) dyes, including indocyanine green (ICG), display an end-tail of the fluorescence emission spectrum detectable in the short-wave infrared (SWIR) window. Imaging methods based on the second...
5.
Bruno S, Luserna di Rora A, Napolitano R, Soverini S, Martinelli G, Simonetti G
J Exp Clin Cancer Res
. 2022 Apr;
41(1):159.
PMID: 35490245
Cell division cycle 20 homologue (CDC20) is a well-known regulator of cell cycle, as it controls the correct segregation of chromosomes during mitosis. Many studies have focused on the biological...
6.
Lucchesi A, Napolitano R, Bochicchio M, Giordano G, Napolitano M
Int J Mol Sci
. 2021 Nov;
22(21).
PMID: 34768772
Current cytoreductive and antithrombotic strategies in MPNs are mostly based on cell counts and on patient's demographic and clinical history. Despite the numerous studies conducted on platelet function and on...
7.
Luserna di Rora A, Ghetti M, Ledda L, Ferrari A, Bocconcelli M, Padella A, et al.
Cell Biol Toxicol
. 2021 Sep;
39(3):795-811.
PMID: 34519926
Doxorubicin (Dox) is one of the most commonly used anthracyclines for the treatment of solid and hematological tumors such as B-/T cell acute lymphoblastic leukemia (ALL). Dox compromises topoisomerase II...
8.
Simonetti G, Mengucci C, Padella A, Fonzi E, Picone G, Delpino C, et al.
Leukemia
. 2021 Jul;
35(10):2813-2826.
PMID: 34193978
Although targeting of cell metabolism is a promising therapeutic strategy in acute myeloid leukemia (AML), metabolic dependencies are largely unexplored. We aimed to classify AML patients based on their metabolic...
9.
Napolitano R, De Matteis S, Carloni S, Bruno S, Abbati G, Capelli L, et al.
Oncol Rep
. 2020 Sep;
44(4):1561-1573.
PMID: 32945487
Tumor protein p53 is a key regulator of several cellular pathways, including DNA repair, cell cycle and angiogenesis. Kevetrin exhibits p53‑dependent as well as‑independent activity in solid tumors, while its...
10.
Lucchesi A, Carloni S, De Matteis S, Ghetti M, Musuraca G, Poggiaspalla M, et al.
Br J Haematol
. 2019 Dec;
189(2):335-338.
PMID: 31792942
This study was conducted to evaluate the expression of fibrinogen receptors on platelets of Philadelphia-negative chronic myeloproliferative neoplasm (MPN) patients. We collected blood samples from 40 consecutive MPN patients and...